



21 September 2017

Carl Zeiss Meditec to unveil in vivo Digital Biopsy Tool on 3rd October 2017

The Carl Zeiss Meditec (CZM) “Digital Biopsy Tool”, based on Optiscan (OIL) technology, will be unveiled and available for exclusive hands-on sessions at two major Neurosurgery events in October 2017:

- The European Association of Neurosurgical Societies meeting in Venice, Italy 1st – 5th of October, and;
- The Congress of Neurological Surgeons which will be held in Boston, MA 7th – 11th October.

CZM has started preparations for regulatory approvals. Once regulatory approval has been achieved in markets such as the United States, Europe and other global regions, the clinical “Digital Biopsy Tool” can be marketed by CZM. The “Digital Biopsy Tool” system will be sold into clinical markets around the world once regulatory approvals are obtained for each location.

OIL and CZM have had a long-standing collaboration agreement focused on the integrated development of a miniaturised confocal imaging probe based system, specifically designed for in vivo real time digital imaging for clinical use in neurosurgery.

This is a significant milestone for the commercialisation of the OIL patented technology into a major clinical application.

Archie Fraser
Chief Executive Officer
E: afraser@optiscan.com

About Optiscan

Optiscan is the world leader in the development and manufacture of high-resolution Miniaturised Confocal Endomicroscopes for Clinical and Preclinical Research markets.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia